On winning Pre-Seed funding with the "Low Inclusion" fiber thesis - Jens & Ida, Ora Biotics

Episode 78: Ora Biotics: Jens Eklöf & Ida Krogh Sjöholm on winning Pre-Seed funding with the "Low Inclusion" fiber thesis 

In this episode, I sit down with Jens Eklöf (CEO/CTO) and Ida Krogh Sjöholm (Commercial Officer), the co-founders of Ora Biotics, a Danish startup developing the next generation of precision prebiotics. They share the tactical playbook of how they cold-called their way to a €300k pre-seed round led by Rockstart and Delphinus Venture Capital, specifically designed to fund their critical €300k US-based human clinical trial. We discuss why they pair a commercial co-founder with a technical lead from day one, how they utilized €60k in Danish government grants to survive their first year, and the exact science of why "low inclusion" fibers bypass the heavy CapEx traps that destroy other ingredient startups. 

🎧 Listen to the full episode to hear how they navigated the delicate "founder spouse" conversation regarding runway and salary expectations.

Key Facts Ora Biotics:

• Goal: To produce a highly targeted, precision prebiotic fiber for metabolic health that does not cause bloating and remains 100% stable in challenging applications like acidic beverages and gummies.
• Milestone: Raised a ~€300k pre-seed round (post-money cap below €2M) from Rockstart and Delphinus Venture Capital.

Alex’s Top Findings: 

1. The "Low Inclusion" Margin Moat. The fundamental problem with most fiber startups is that they require massive doses to be effective, which forces brands to alter recipes and forces the startup to build massive, CapEx-heavy production facilities to hit volume targets. Ora Biotics solves this by targeting specific gut bacteria, meaning their fiber requires a very low dose to be effective. This "low inclusion rate" means they can command high margins while relying entirely on asset-light Contract Manufacturers (CDMOs). "If you have lower inclusion, it's also easier to make it a drop-in solution to whatever product you just happen to have... The dose is certainly our key to get really nice margins already from the beginning. We are producing with contract manufacturers, right? We are not building a big optimized production line ourselves."
2. De-Risking with the "Gold Standard" Clinical Trial. While fiber can be sold legally as a food ingredient without a clinical trial, major FMCG brands will not risk their reputation (or lawsuits, a la Olipop) on unsubstantiated health claims. Orbiotics specifically raised their €300k round to fund a randomized, placebo-controlled human study in the US. This data is the exact milestone investors demanded to unlock the next funding round. "If you want to say anything about the health benefits in almost all markets in the world, you need to substantiate that... if you are a big brand and you want to know and you want the integrity to know that the ingredient you put in there gives the benefits... you want a human study. And that's also what we want to go for."
3. The Power of the Commercial Co-Founder at Pre-Seed. Many deep-tech startups fail because they are led by purely technical founders who wait years to speak to customers. Ora Biotics brought Ida (Commercial Officer) on board at the very beginning. Her ability to define the B2B strategy, handle investor storytelling, and secure Letters of Intent (LOIs) for food-grade sample testing before the product was even finalized was critical to winning their pre-seed funding. "I worked more on the storytelling and the market positioning and all of that, which is my background, right? I have a commercial background, I'm not a scientist... We have a few companies now who have said that they've signed the LOAs. They want to test it in their applications. So I think that is an opener."